Antibiotic Resistant Infection, Critical Illness, Sepsis, SIRS
Conditions
Keywords
CD64 antigens, Biomarkers, Granulocyte Colony-Stimulating Factor, Interleukin-4, Interferon-gamma, C-reactive protein, lipopolysaccharide-binding protein, procalcitonin, Cytokines, Patients, Human, Systemic Inflammatory Response Syndrome, Sepsis, Infection, Antibiotics, Intensive Care Units, Point-of-Care Systems, Bedside Testing
Brief summary
The purpose of the study is to find out whether CD64 expression on neutrophils measured by a new bedside test (LeukoDx) within 30 minutes is associated with effective antibiotic therapy in critically ill adult patients at risk of sepsis.
Detailed description
In the present study, in critically ill patients with suspected infection undergoing application of antibiotics, CD64 and inflammatory plasma markers will be determined on days 1 to 4. CD64 expression on the surface of neutrophils will be determined by fluorescence activated cell sorter (FACS) and with a new bedside test (LeukoDx). The purpose of the study is to clarify: 1. Is CD64 expression on neutrophils associated with effective antibiotic therapy in critically ill adult patients at risk of sepsis? 2. Is CD64 expression associated with distinct plasma parameters of inflammation? 3. Do the results of the gold standard CD64 determination by FACS correlate with those of a new bedside test (LeukoDx)?
Interventions
None listed
Sponsors
University of Ulm
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age \> 18 years * critically ill adult patients * sepsis * SIRS * initiation of antibiotic treatment * patients \< 48 hours after admission on ICU
Exclusion criteria
* multiple admissions on ICU, (\>1 in last 2 weeks period) * leukopenia \< 1 G/l * and thrombocytopenia * rhG-CSF or IFN-gamma therapy up to 1 week before inclusion * participation in another study receiving drugs or biological within the preceeding 30 days * recent longterm corticosteroid treatment * HIV * patients after organ transplantation treated with immunomodulating drugs * pregnant patients or after delivery * life expectancy \< 24 hours * polytraumatized patients with reanimation on scene, or infest prognosis * patients under high dose corticosteroids or chemotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CD64 expression on neutrophils measured by LeukoDx | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Association of course of CD64 expression with effective antibiotic treatment | 1 year |
Other
| Measure | Time frame |
|---|---|
| CD64 expression on neutrophils measured by FACS | 1 year |
| Association of CD64 expression with inflammatory markers | 1 year |
| Association of CD64 expression with cell surface markers on monocytes | 1 year |
Countries
Germany
Outcome results
None listed